Franz Gruswitz

Franz Gruswitz is a seasoned professional in the field of RNA and protein sciences, currently serving as Sr. Director at NextRNA Therapeutics since July 2022, where the focus is on advancing small-molecule drug discovery for novel RNA-targeted therapies. Previous roles include Director and Principal Scientist at Tectonic Therapeutics, and Principal Scientist at Aptevo Therapeutics, specializing in biophysical characterization and method development for bispecific antibodies. Additionally, Gruswitz held positions as Group Leader of Structural Biology at Omeros Corporation and Manager of Membrane Protein Sciences at Beryllium, contributing to membrane protein purification and characterization projects. Experience spans across multiple companies including Takeda, UCSF, Bayer, and Southern Testing & Research Laboratories. Educational credentials include a Ph.D and M.S in Biophysics from the University of Rochester School of Medicine and Dentistry, and a B.S and B.A in Biology and Physics from the University of North Carolina Wilmington.